Related Experiment Video
Updated: Nov 17, 2025
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.7K
Trimetazidine in Heart Failure
Hongyang Shu1,2, Yizhong Peng3, Weijian Hang1,2
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in Pharmacology
|February 18, 2021
Summary
Trimetazidine offers heart failure treatment benefits by improving cardiac metabolism and reducing myocardial damage. This drug acts as an effective adjunct therapy, enhancing patient outcomes in heart failure management.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Heart failure is a complex systemic syndrome with limited treatment efficacy.
- Pathological changes in the myocardium, including metabolic alterations, are central to heart failure development.
- Existing therapies for heart failure do not provide satisfactory outcomes for all patients.
Purpose of the Study:
- To review the pathological changes in the heart during heart failure.
- To emphasize the role of cardiac metabolism in heart failure.
- To discuss the clinical application and cardioprotective mechanisms of trimetazidine in heart failure.
Main Methods:
- Literature review of basic and clinical studies on trimetazidine and heart failure.
- Analysis of trimetazidine's effects on myocardial metabolism, apoptosis, fibrosis, autophagy, and inflammation.
- Evaluation of clinical trial data regarding trimetazidine as an adjunct therapy.
Main Results:
- Trimetazidine demonstrates cardioprotective effects through metabolism modulation.
- It alleviates myocardial apoptosis, fibrosis, autophagy, and inflammation.
- Clinical studies show trimetazidine improves heart failure symptoms when used with conventional treatments.
Conclusions:
- Trimetazidine is a promising adjunct therapy for heart failure.
- Its mechanisms involve metabolic enhancement and reduction of myocardial injury.
- Further research can explore its full potential in heart failure management.
Related Concept Videos
01:30Heart Failure V: Medical Management
88
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
88
01:22Heart Failure Drugs: β-Blockers
553
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
553
01:22Heart Failure Drugs: Diuretics
608
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
608
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
666
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
01:26Heart Failure Drugs: Inotropic Agents
930
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
930
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.3K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.3K